Hypersensitivity: Clinical Trials

627 trials for Hypersensitivity, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

627 completed. 627 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4627Completed 627

Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity

Trials (filtered) newest first · largest first

All 627 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dymista in Chinese Adolescents
Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate - Allergic Rhinitis Due to Allergens
Phase 4CompletedViatris Inc.1002026-05-082026-11-03
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
Skin Testing - Allergy
Phase 4CompletedMayo Clinic212025-11-052026-04-01
IV DEXAMETHASONE VS. METHYLPREDNISOLONE IN CHILDREN WITH SEVERE ASTHMA EXACERBATION
Intravenous Dexamethasone, Intravenous Methylprednisolone - Status Asthmaticus, Asthma (Diagnosis)
Phase 4CompletedIstanbul Medeniyet University1292025-09-012026-07-28
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Lebrikizumab - Atopic Dermatitis
Phase 4CompletedEli Lilly and Company2332025-06-162026-10-15
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
Fexofenadine HCL and pseudoephedrine HCL - Rhinitis Allergic
Phase 4CompletedSanofi2032025-06-152026-02-17
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
Garadacimab - Hereditary Angioedema
Phase 4CompletedCSL Behring182025-04-282026-07-23
Evaluation of Treatments for Allergic Rhinitis (Rhinal 2)
ALLERSPRAY-G (device A), PCNS (device B) - Allergic Rhinitis
Phase 4CompletedUniversity Hospital, Clermont-Ferrand352025-03-032025-06-13
Oxymetazoline Bridge Therapy With Intranasal Corticosteroids in Pediatric Allergic Rhinitis
Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg, Oxymetazoline 0.05% nasal solution - Persistent Allergic Rhinitis
Phase 4CompletedDr. Behcet Uz Children's Hospital762025-01-022026-05-18
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia
Penehyclidine hydrochloride, Normal Saline - Respiratory Hypersensitivity, Perioperative Respiratory Adverse Events
Phase 4CompletedSun Yat-sen University2042024-11-122026-10-02
Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
Budesonide-Formoterol treatment - Cough-Variant Asthma
Phase 4CompletedAstraZeneca10002024-10-182025-09-18
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE)
Phase 4CompletedNang Kuang Pharmaceutical Co., Ltd.52024-09-272025-12-18
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Albuterol/Budesonide, Albuterol - Mild Asthma
Phase 4CompletedAstraZeneca1012024-09-112026-02-27
Evaluation of Time-Sensitive Nebulization Mode Converter
Cross-over Nebulization Modes Comparison System - Aerosol Therapy, Asthma
Phase 4CompletedBeni-Suef University362024-09-012026-06-08
A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients
Mirabegron 100 mg, Mirabegron 50mg, mirabegron 25 mg - Cirrhosis, Asthma
Phase 4CompletedKafrelsheikh University782024-07-012026-04-16
FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA
Omalizumab - Food Allergy
Phase 4CompletedAAADRS Clinical Research Center242024-06-032026-10-28
BenRalizumab Effect on Airway Remodeling in Severe asTHma
Benralizumab 30 mg/ml - Asthma; Eosinophilic, Airway Remodeling
Phase 4CompletedAristotle University Of Thessaloniki362024-03-012026-10-28
Bioequivalence Study of Methacholine for Inhalation (pharmacodynamics)
Test preparation:Methylcholine chloroacetate for inhalation, Reference preparation:Methylcholine chloroacetate for inhalation(Provocholine) - Asthma
Phase 4CompletedChina-Japan Friendship Hospital402024-02-242024-12-10
Individualizing Treatment for Asthma in Primary Care
Asthma Symptom Monitoring online tools, Inhaled Steroids, Azithromycin Pill - Asthma, Bronchial Diseases
Phase 4CompletedDARTNet Institute1032024-02-012025-04-20
Reversibility of Methacholine Induced Bronchoconstriction
salbutamol aqueous solution, salbutamol pressurized metered dose inhaler, placebo - Asthma
Phase 4CompletedUniversity of Saskatchewan162024-01-122026-05-04
A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children
Salbutamol (Ventolin®), salbutamol + ipratropium bromide nebules - Asthma Exacerbation, Children
Phase 4CompletedChildren's Hospital and Institute of Child Health, Multan602024-01-012025-04-09

Showing 20 of 627. Sign in to see all of them.

Narrower conditions

Asthma (310)  ·  Dermatitis, Atopic (87)  ·  Rhinitis, Allergic (75)  ·  Rhinitis, Allergic, Seasonal (48)  ·  Conjunctivitis, Allergic (32)  ·  Rhinitis, Allergic, Perennial (30)  ·  Eczema (18)  ·  Pulmonary Disease, Chronic Obstructive (18)  ·  Rhinitis (14)  ·  Pulmonary Eosinophilia (10)  ·  Urticaria (10)  ·  Chronic Urticaria (9)  ·  Respiratory Hypersensitivity (9)  ·  Angioedemas, Hereditary (7)

Broader conditions

Immune System Diseases (625)  ·  Hypersensitivity, Immediate (590)  ·  Respiratory Tract Diseases (444)  ·  Respiratory Hypersensitivity (428)  ·  Lung Diseases (315)  ·  Bronchial Diseases (314)  ·  Lung Diseases, Obstructive (311)  ·  Otorhinolaryngologic Diseases (143)  ·  Nose Diseases (142)  ·  Rhinitis (126)  ·  Skin and Connective Tissue Diseases (119)  ·  Skin Diseases (118)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (94)  ·  Genetic Diseases, Inborn (94)

Interventions

Fluticasone (60)  ·  montelukast (49)  ·  Albuterol (36)  ·  Budesonide (33)  ·  Omalizumab (29)  ·  Fluticasone-Salmeterol Drug Combination (27)  ·  desloratadine (24)  ·  levocetirizine (20)  ·  fexofenadine (18)  ·  pimecrolimus (18)  ·  Mometasone Furoate (17)  ·  Olopatadine Hydrochloride (17)  ·  dupilumab (17)  ·  Salmeterol Xinafoate (16)  ·  Cetirizine (15)

Sponsors

GlaxoSmithKline (61)  ·  Organon and Co (42)  ·  AstraZeneca (24)  ·  Sanofi (19)  ·  Novartis (16)  ·  Alcon Research (14)  ·  University of Dundee (12)  ·  University of Saskatchewan (11)  ·  Centre of Chinese Medicine, Georgia (8)  ·  University of Chicago (8)  ·  Astellas Pharma Inc (7)  ·  Imperial College London (7)  ·  Medical University of Lodz (7)  ·  Novartis Pharmaceuticals (6)  ·  UCB Pharma (6)

Countries

United States (232)  ·  Canada (62)  ·  United Kingdom (57)  ·  Germany (45)  ·  Italy (37)  ·  France (27)  ·  Spain (27)  ·  Belgium (22)  ·  Netherlands (22)  ·  Poland (22)  ·  China (19)  ·  Denmark (18)  ·  Sweden (15)  ·  Australia (13)  ·  South Korea (13)

Top investigators

Don Cockcroft, MD (6)  ·  Manana Tchaia, MD (6)  ·  Merab Lomia, MD, PhD (6)  ·  Phyllis Diener (6)  ·  Brian Lipworth, MD (4)  ·  Leslie Hendeles, PharmD (4)

Results publications

PMID 20167147, PMID 20642206, PMID 25260889, PMID 32298853, PMID 33369570, PMID 36472162, PMID 37347518, PMID 37536444, PMID 37952772, PMID 11558866, PMID 12045120, PMID 12612294, PMID 15922813, PMID 16140398, PMID 16278257, PMID 16597501, PMID 16687712, PMID 16846553, PMID 16913264, PMID 17046300, PMID 17075269, PMID 17507702, PMID 17585003, PMID 17610727, PMID 17629923, PMID 17766511, PMID 18256392, PMID 18263672, PMID 18331513, PMID 18399898, PMID 18430310, PMID 18583517, PMID 18990678, PMID 19127072, PMID 19133920, PMID 19134016, PMID 19164187, PMID 19187327, PMID 19291931, PMID 19302250, PMID 19403473, PMID 19428097, PMID 19467341, PMID 19496252, PMID 19504468, PMID 19557208, PMID 19632710, PMID 19663124, PMID 19696440, PMID 19788025

NIH funding

2015 (5), 2019 (4), 2004 (3), 2014 (3), 2017 (3), 2018 (3), 2016 (2), 2005 (1), 2008 (1), 2023 (1), P50HL056385 (1), R01AI116658 (1), R01DK101856 (1), R01HL109293 (1), R01HL114899 (1)